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Abstract
Persistent infection with high-risk (HR) human papillomavirus (HPV) types is necessary for cervical cancer development. However, little
is known about the inﬂuence of multiple HPV infections on cervical lesion risk. The aim of this study was to evaluate the frequency of
single and multiple HPV infections in Portuguese women, and to assess the frequency of multiple infections in cervical intraepithelial
neoplasia (CIN). HPV prevalence, type-speciﬁc prevalence and extent of multiple infections were assessed in 1057 cervical samples. The
Clinical Array HPV assay was used to detect 35 HPV types. According to histological diagnosis, 425 samples were normal, 375 were
CIN1, and 257 were CIN2+. HPV status was studied in relation to age and lesion severity. The prevalence of HPV infection was 52.7%;
25.4%, 67.2% and 76.7% were positive for any HPV type in the normal, CIN1 and CIN2+ cases, respectively. Among HPV-positive cases,
32.0% were associated with multiple infections. Among multiple infections, 96.1% harboured HR HPV types and 38.2% HR–low risk
(LR) HPV types. Overall, 33 different HPV types (18 HR and 15 LR) were detected. HR HPV types (44.1%) were signiﬁcantly more pre-
valent than LR HPV types (8.6%). The most frequent genotype was HPV 16 (25.5%), followed by HPV 31, 53, 66, 58, and 51. Multiple
infections showed a signiﬁcant increase (p 0.005) according to severity of neoplasia, particularly for HR–HR HPV infections (p 0.003).
No association between age and multiple HPV infections was observed (p 0.812). However, multiple HR HPV infections were more
frequent in women under 30 years of age (35.3%).
Keywords: Cervical neoplasia, genotyping, microarray, multiple infections, type-speciﬁc HPV
Original Submission: 27 May 2010; Revised Submission: 17 September 2010; Accepted: 23 September 2010
Editor: J.-M. Pawlotsky
Article published online: 5 October 2010
Clin Microbiol Infect 2011; 17: 941–946
10.1111/j.1469-0691.2010.03387.x
Corresponding author: A. Pista, Departamento de Doenc¸as
Infecciosas, Instituto Nacional de Sau´de Doutor Ricardo Jorge I.P.,
Av. Padre Cruz, 1649-016 Lisboa, Portugal
E-mail: angela.pista@insa.min-saude.pt
*These authors participated equally in the study.
Introduction
Cervical cancer is the third most common malignancy of
the female genital system, and is the second most common
cancer in women worldwide [1].
Clinical and subclinical human papillomavirus (HPV) infec-
tions are the most common sexually transmitted infections in
the world. On the basis of molecular epidemiological evidence,
HPV types can be classiﬁed into high-risk (HR) types, which
are frequently associated with the development of premalig-
nant and malignant epithelial lesions of the cervix, and low-risk
(LR) types, which are found mainly in condylomata acuminata
(genital warts) and benign lesions, including a large proportion
of low-grade squamous intraepithelial lesions [2,3].
Portugal has a relatively high incidence rate for cervical can-
cer (13.5/100 000) and one of the highest mortality rates (4.5/
100 000) in the European Union [4], mainly because of a limited
population-based screening programme for cervical cancer.
Persistent HR HPV infection has been well established as
the central cause of cervical cancer [2,5,6]. For this reason,
interest has increased in the detection of HPV DNA for
primary cervical screening [7–9]. The development of new
commercial assays has improved the quality of HPV detection
and genotyping, and revealed the presence of multiple HPV
infections in women with and without cytological abnormali-
ties. To date, 20–50% of HPV-positive women have been
reported to be infected with multiple HPV types [10–12].
Co-infection with more than one HPV type has been observed
more frequently among young women and among those with
cytological abnormalities or an impaired immune response
[6,13–21].
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However, the clinical importance of co-infection with mul-
tiple HPV types remains a controversial area of investigation.
In some studies, these infections have been associated with
persistent infections and with a higher risk for cervical intra-
epithelial neoplasia (CIN) [14,16,18,19,21,22], whereas other
studies have reported no increased risk for CIN or cervical
cancer development in women infected with multiple HPV
types, as compared with women with single-type infections
[6,13,15,20].
In Portugal, limited data are available concerning the distri-
bution of HPV genotypes as single or multiple infections.
Therefore, the main purpose of this study was to evaluate
the frequency of single and multiple HPV infections in Portu-
guese women, and to assess the frequency of multiple infec-
tions in CIN.
The identiﬁcation of multiple HPV types in different grades
of cervical neoplasia may provide important information
about the impact of single/multiple HPV type-speciﬁc associa-
tions as a risk factor for the persistence and progression of
cervical neoplasia, and could be helpful for appropriate cervi-
cal cancer prevention strategies.
Materials and Methods
Clinical samples
This study was carried between January 2006 and December
2008 in the Lisbon area and in the southern region of Portugal.
The study population comprised 1500 sexually active women,
attending primary healthcare clinics of the National Health
Service and gynaecological outpatient clinics, who were
referred to the National Institute of Health for opportunistic
screening and for evaluation of HPV-associated lesions.
Although not representative of the general population, the
studied group includes a high proportion of women at risk for
cervical cancer and a broad range of outcomes. Women who
were pregnant, had undergone hysterectomy or had been
treated for CIN within the last 12 months were excluded.
Cervical cell samples were obtained with a cytobrush dur-
ing clinical examination for cytological analyses (Pap smears).
The residual exfoliated cells were stored at )20C until
DNA extraction. The ﬁnal diagnosis of the women with
abnormal cytology was made by histological evaluation on
colposcopically directed biopsies. Outcome was deﬁned as
normal (normal cytology and/or negative biopsy), CIN1 or
CIN2 or worse (CIN2+) on cytological/histological examina-
tion [23]. Both diagnoses (cytological and histological) were
conﬁrmed by experienced pathologists.
All women provided voluntary written informed consent
for the tests and answered a questionnaire. The study proto-
col was approved by the sponsored competent ethical
review committees.
HPV DNA detection
DNA was extracted manually from all cervical specimens.
Cell suspensions were digested with 100 lg/mL proteinase K
for 3 h at 56C, and puriﬁed by spin-column chromatogra-
phy. Nucleic acids were resuspended in a ﬁnal volume of
100 lL and stored at )20C until use for PCR ampliﬁcation.
Genotyping was performed by using the Clinical Array HPV
Assay (now CLART HPV 2; Genomica, Madrid, Spain), accord-
ing to the manufacturer’s procedures. This methodology uses
biotinylated primers that amplify a 450-bp fragment within
the HPV L1 region. Co-ampliﬁcation of an 892-bp region of
the cystic ﬁbrosis transmembrane conductance regulator
gene and a 1202-bp fragment of a transformed plasmid pro-
vides a control to ensure DNA extraction adequacy and
PCR efﬁciency. Amplicons are detected by hybridization in a
low-density microarray containing triplicate DNA probes
speciﬁc to 35 types (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39,
40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68,
70, 71, 72, 73, 81, 82, 83, 84, 85, and 89). Semiquantitative
results can be obtained in an automatic reader.
In this study, HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 68, 70, 73 and 82 were considered as HR
HPV (including probable and possible HR types), and HPV 6,
11, 40, 42, 43, 44, 54, 61, 62, 71, 72, 81, 83, 84, 85 and 89
as LR HPV (including unclassiﬁed types) [2,24].
Statistical analysis
To determine the prevalence of HR HPV and LR HPV types,
cases were counted more than once if they harboured a multi-
ple infection with a mixture of both. The prevalence of individ-
ual HPV types was determined as they appeared in single or in
multiple infections. Multiple HPV infection was deﬁned as two
or more HPV types detected. For multiple HPV infections, the
proportion was assessed in relation to severity of lesion, and
compared with data from women harbouring a single HPV
infection. Data were analysed using the chi-squared test, and,
when appropriate, Fisher’s exact test to calculate all p-values.
The ORs, together with 95% CIs, were computed with the
use of 2 · 2 contingency tables. All analyses were performed
with SPSS version 17.0 software. Differences were considered
to be statistically signiﬁcant when p-values were <0.05.
Results
Of the 1500 selected women, 443 were excluded because
they were not eligible or were considered to be inadequate
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for HPV testing. Therefore, a total of 1057 women aged 18–
67 years (mean age, 34.3 ± 10.6 years; median age, 33 years)
were assigned for this study. All women were sexually active,
40% reported having had more than one regular sexual part-
ner, 49.5% had never used oral contraceptives, 18.6% were
current smokers, and 12.9% were former smokers. Cases
were stratiﬁed by clinical diagnosis and by age (Table 1).
HPV DNA was detected in 52.7% (557/1057) of the stud-
ied women. According to the clinical diagnosis, the positivity
rate for any HPV type was 25.4% (108/425) in the normal
cases, 67.2% (252/375) in the CIN1 cases, and 76.7% (197/
257) in the CIN2+ cases. Overall, HR HPV types (44.1%)
were signiﬁcantly more prevalent than LR HPV types (8.6%)
(p 0.000) (82.0% and 18.0% among positive cases, respec-
tively) (Table 2). According to the severity of CIN, HR HPV
types were detected in 55.2% (207/375) of the women with
CIN1 and in 73.2% (188/257) of the women with CIN2+. In
those with normal cytology, the prevalence of HR HPV types
was 16.7% (71/425). There were nine cases of CIN2+ (3.5%)
associated with infection by LR HPV types (Table 2).
HPV infection was more common in younger women
(55.9% in women aged <30 years vs. 50.1% in those aged
‡30 years; p 0.035). The same was observed for HR HPV
types (45.8% vs. 42.7%; p 0.032).
Multiple infections were detected in 16.8% (178/1057) of
the women (representing 32.0% of the positive samples; 178/
557); 107 had two HPV types, 51 had three HPV types, and 20
had at least four genotypes. The most common co-infection
was by HR–HR HPV types (18.5%; 103/557; HPV 16/31, 3.9%),
whereas infections by HR–LR and LR–LR HPV types were
identiﬁed in 12.2% (68/557; HPV 16/6, 5.1%) and 1.3% (7/557;
HPV 61/62, 0.6%), respectively (representing 9.7%, 6.4% and
0.7% of the overall population) (Table 3). Multiple HPV pat-
terns are not shown, because of their great variability.
According to diagnosis, the prevalence of multiple infec-
tions was 19.4% (21/108) in normal cases, 32.9% (83/252) in
CIN1 cases, and 37.6% (74/197) in CIN2+ cases (Table 3).
Multiple infections showed a signiﬁcant increase (p 0.005)
according to severity of neoplasia, particularly for HR–HR
HPV infections (p 0.003). The OR for CIN2+ was 2.49
(95% CI 1.43–4.35, p 0.001) for women with multiple HPV
infections, rising to 4.03 (95% CI 1.63–9.97, p 0.001) for
those with HR–HR multiple infections (Table 4). Neverthe-
less, multiple infection and HR HPV types were shown to be
independent factors for lesion severity.
No association between age and multiple HPV infections
was observed (p 0.812). However, multiple infections were
more frequent in women under 30 years of age (35.3% vs.
28.9% in women above 30 years of age), although not signiﬁ-
cantly (Table 3).
In total, 33 different HPV types (18 HR and 15 LR types)
were detected. The greatest diversity was found in CIN1 cases
(31 HPV types vs. 29 in CIN2+ cases and 25 in normal cases).
The prevalence of the 13 most common HPV types in
single and multiple infections is presented in Table 5. Among
TABLE 1. Characteristics of the studied cervical samples
N (%)
Cytological results (n = 1057)
Normal 425 (40.2)
LSIL 375 (35.5)
HSIL 247 (23.4)
SCC 10 (0.9)
Histological results (n = 325)
Normal 117 (36.0)
CIN1 142 (43.7)
CIN2 24 (7.4)
CIN3 41 (12.6)
SCC 1 (0.3)
ND 732
Clinical diagnosis (cytology + biopsy; n = 1057)
Normal 425 (40.2)
CIN1 375 (35.5)
CIN2+ 257 (24.3)
Age group (years) (n = 1057)
<30 476 (45.0)
‡30 581 (55.0)
CIN1, cervical intraepithelial neoplasia grade 1; CIN2, cervical intraepithelial
neoplasia grade 2; CIN2+, cervical intraepithelial grade 2 or worse; CIN3; cervi-
cal intraepithelial neoplasia grade 3; LSIL, low-grade squamous intraepithelial
lesion; HSIL, high-grade squamous intraepithelial lesion; ND, not determined;
SCC, squamous cell carcinoma.
TABLE 2. Human papillomavirus (HPV) prevalence according to diagnosis and age
Diagnosis Age (years)
Total
(n = 1057)
Normal
(n = 425)
CIN1
(n = 375)
CIN2+
(n = 257)
<30
(n = 476)
‡30
(n = 581)
n (%) n (%) n (%) n (%) n (%) n (%)
Infection
HP VDNA-negative 317 (74.6) 123 (32.8) 60 (23.3) 210 (44.1) 290 (49.9) 500 (47.3)
HP VDNA-positive 108 (25.4) 252 (67.2) 197 (76.7) 266 (55.9) 291 (50.1) 557 (52.7)
HR HPV DNA-positive 71 (16.7) 207 (55.2) 188 (73.2) 218 (45.8) 248 (42.7) 466 (44.1)
LR HPV DNA-positive 37 (8.7) 45 (12.0) 9 (3.5) 48 (10.1) 43 (7.4) 91 (8.6)
CIN1, cervical intraepithelial neoplasia grade 1; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; HR, high-risk; LR, low-risk.
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carcinogenic HPV types, HPV 16 (25.5%; 142/557) was the
most prevalent, followed by HPV 31 (11.5%; 64/557),
HPV 53 (11.1%; 61/557), HPV 66 (10.4%; 58/557), HPV 58
(9.7%; 54/557), and HPV 51 (9.3%; 52/557). Among the LR
HPV types, the most common were HPV 6 (8.4%; 47/557),
HPV 61 (5.9%; 33/557), and HPV 84 (5.4%; 30/557). For the
remaining HPV types, detection rates varied between 3.9%
(22/557) and 0.2% (1/557). HPV 16 was the most prevalent
genotype in all lesion grades, either as a single infection or
combined with other types. The prevalence of HPV 16 and/
or 18 increased with the severity of cervical neoplasia
(51.8% in CIN2+ cases, 19.4% in CIN1 cases, and 22.2% in
normal cases) (Table 5). Overall, 22.0% (233/1057) of the
women were infected by HPV 6/11/16/18, 13.4% (142/1057)
were infected by HPV 16, 3.1% (33/1057) by HPV 18, and
0.4% (4/1057) by HPV 16/18. No cases of infection by
HPV 6/11/16/18 were observed.
Discussion
At present, it is not clear whether infection by multiple HPV
types can serve as a predictor for the state and severity of
disease. However, several studies have provided evidence
that multiple HPV infection seems to be associated with a
signiﬁcantly increased risk of high-grade neoplasia as com-
pared with single infection [14,16,18,19,21].
TABLE 3. Single and multiple human papillomavirus (HPV) infection stratiﬁed by diagnosis and age (n = 557)
Diagnosis Age (years)
Total
(n = 557)
Normal
(n = 108)
CIN1
(n = 252)
CIN2+
(n = 197)
<30
(n = 266)
‡30
(n = 291)
n (%) n (%) n (%) n (%) n (%) n (%)
Type of HPV infection
Single infections 87 (80.6) 169 (67.1) 123 (62.4) 172 (64.7) 207 (71.1) 379 (68.0)
Single HR HPV 52 (48.1) 127 (50.4) 116 (58.9) 127 (47.7) 168 (57.7) 295 (53.0)
Single LR HPV 35 (32.4) 42 (16.7) 7 (3.6) 45 (16.9) 39 (13.4) 84 (15.1)
Multiple infections 21 (19.4) 83 (32.9) 74 (37.6) 94 (35.3) 84 (28.9) 178 (32.0)
Multiple HR–HR HPV 6 (5.6) 43 (17.1) 54 (27.4) 56 (21.1) 47 (16.2) 103 (18.5)
Multiple HR–LR HPV 13 (12.0) 37 (14.7) 18 (9.1) 35 (13.2) 33 (11.3) 68 (12.2)
Multiple LR–LR HPV 2 (1.9) 3 (1.2) 2 (1.0) 3 (1.1) 4 (1.4) 7 (1.3)
CIN1, cervical intraepithelial neoplasia grade 1; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; HR, high-risk; LR, low-risk.
TABLE 4. ORs and 95% CIs of human papillomavirus (HPV)
infection in CIN1 and CIN2+ cases as compared with cyto-
logically/histologically normal cases
Variable OR (95% CI) p-value
CIN1
Negative 0.1997 (0.1433–0.2784) <0.0001
Single Reference
Multiple 0.4915 (0.2852–0.8469) 0.009
LR HPV single 0.4913 (0.2827–0.8538) 0.011
HR HPV single Reference
LR–LR HPV multiple 0.6142 (0.0997–3.7834) ND
LR–HR HPV multiple 1.1654 (0.5732–2.3693) 0.671
HR–HR HPV multiple 2.9344 (1.1775–7.3125) 0.016
CIN2+
Negative 0.1339 (0.0907–0.1976) <0.0001
Single Reference
Multiple 2.4925 (1.4280–4.3503) 0.001
LR HPV single 0.0897 (0.0374–0.2152) <0.0001
HR HPV single Reference
LR–LR HPV multiple 0.4483 (0.0615–3.2701) ND
LR–HR HPV multiple 0.6207 (0.2832–1.3606) 0.230
HR–HR HPV multiple 4.0345 (1.6327–9.9696) 0.001
CIN1, cervical intraepithelial neoplasia grade 1; CIN2+, cervical intraepithelial
neoplasia grade 2 or worse; HR, high-risk; LR, low-risk; ND, not determined.
TABLE 5. Prevalence of the 13 most common human papil-
lomavirus (HPV) types according to lesion severity
(n = 557)
HPV type
Type of
infection
Diagnosis
Total
(n = 557)
Normal
(n = 108)
CIN1
(n = 252)
CIN2+
(n = 197)
n (%) n (%) n (%) n (%)
16 Single 16 (14.8) 23 (9.1) 44 (22.3) 83 (14.9)
Multiple 6 (5.6) 19 (7.5) 34 (17.3) 59 (10.6)
18 Single 2 (1.9) 5 (2.0) 9 (4.6) 16 (2.9)
Multiple 0 (0.0) 2 (0.8) 15 (7.6) 17 (3.1)
31 Single 5 (4.6) 19 (7.5) 16 (8.1) 40 (7.2)
Multiple 1 (0.9) 7 (2.8) 16 (8.1) 24 (4.3)
33 Single 1 (0.9) 3 (1.2) 3 (1.5) 7 (1.3)
Multiple 0 (0.0) 6 (2.4) 9 (4.6) 15 (2.7)
45 Single 0 (0.0) 1 (0.4) 5 (2.5) 6 (1.1)
Multiple 1 (0.9) 3 (1.2) 5 (2.5) 9 (1.6)
51 Single 2 (1.9) 6 (2.4) 10 (5.1) 18 (3.2)
Multiple 5 (4.6) 17 (6.7) 12 (6.1) 34 (6.1)
53 Single 8 (7.4) 16 (6.3) 10 (5.1) 34 (6.1)
Multiple 1 (0.9) 14 (5.6) 12 (6.1) 27 (4.8)
58 Single 5 (4.6) 12 (4.8) 8 (4.1) 25 (4.5)
Multiple 3 (2.8) 15 (6.0) 11 (5.6) 29 (5.2)
66 Single 6 (5.6) 19 (7.5) 5 (2.5) 33 (5.9)
Multiple 5 (4.6) 15 (6.0) 8 (4.1) 28 (5.0)
70 Single 4 (3.7) 4 (1.6) 0 (0.0) 8 (1.4)
Multiple 2 (1.9) 9 (3.6) 3 (1.5) 14 (2.5)
6 Single 9 (8.3) 7 (2.8) 2 (1.0) 18 (3.2)
Multiple 7 (6.5) 13 (5.2) 9 (4.6) 29 (5.2)
61 Single 4 (3.7) 9 (3.6) 0 (0.0) 13 (2.3)
Multiple 2 (1.9) 8 (3.2) 10 (5.1) 20 (3.6)
84 Single 4 (3.7) 2 (0.8) 0 (0.0) 6 (1.1)
Multiple 4 (3.7) 8 (3.2) 12 (6.1) 24 (4.3)
CIN1, cervical intraepithelial neoplasia grade 1; CIN2+, cervical intraepithelial
neoplasia grade 2 or worse.
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This was the largest cross-sectional study describing the
frequency of single and multiple infections in CIN in Portu-
guese women who were referred for opportunistic screening
and for evaluation of HPV-associated lesions. As limited data
are available, the ﬁndings reported here provide further
insights into HPV epidemiology in Portugal.
Overall, HPV DNA was detected in 52.7% of the studied
women, which was a higher rate than has been found in other
European populations [21,25–27]. According to other studies,
the HPV prevalence in Portuguese women with normal cytol-
ogy ranges from 15.5% [27] to 16.5%, whereas in this study
the prevalence was 25.4%. However, the enrolled population
and the outcomes had different characteristics; one study was
carried out in a group of 279 women with cytological diagno-
sis followed at the Portuguese Institute of Oncology of Coim-
bra [27], and the other was a population-based study in
women with cytological results. Data comparisons are difﬁ-
cult, as study designs, outcome measures, HPV genotyping
assays and grouping of genotypes vary between studies.
HR HPV types were more frequent than LR HPV types
(44.1% vs. 8.6%). In our population, HPV 16 was the most
prevalent type in all lesion grades, either as a single infection
or combined with other genotypes, followed by HPV 31, 53,
66, 58, and 51. The prevalence of HPV 16 and/or 18
increased with the severity of cervical neoplasia, which is in
line with previous reports [25,28]. In spite of this, nine cases
of CIN2+ were associated with LR HPV types, as single or
as multiple LR–LR infections.
The high prevalence of HPV 31, 53 and 66 in the studied
population has already been reported by other studies
[20,29,30]. Recent migration from HR regions for cervical can-
cer, such as Brazil and sub-Saharan Africa, could explain the
relevance of these HPV types in Portuguese women, suggest-
ing that is important to evaluate type-speciﬁc HPV distribution.
On the basis of our data, vaccines against HPV 16/18 have the
potential to prevent 51.8% of CIN2+ lesions, and this preven-
tive potential may be higher if cross-protection against other
HR HPV types is taken into account, namely for HPV 31.
Multiple HPV infections were detected in 32.0% of the
positive women, which is similar to what has been found in
other studies [6,10–21].
As expected, our data showed that the HPV prevalence
was signiﬁcantly higher in women below 30 years of age,
who usually have higher levels of sexual activity. Although
the difference was not signiﬁcant, women with multiple infec-
tions were younger than women with single HPV infections.
Younger age is frequently associated with an increased rate
of multiple HPV infections, which corroborates the impor-
tance of demographic and behavioural variables for HPV
acquisition [10,16,21,25]. However, this inverse correlation
can also be attributed to the development of acquired immu-
nity over time after exposure [31,32].
Only follow-up studies of a large number of women with
incident HPV infections can give reliable estimates of type-
speciﬁc prognosis. However, such studies are costly and
time-consuming. In cross-sectional studies, the distribution of
HPV infection according to severity of CIN can highlight the
oncogenic potential of the different HPV types, either as sin-
gle or as multiple infections. According to cytological diagno-
sis, a high prevalence of multiple HR HPV infections occurs
in both low-grade and high-grade lesions, reﬂecting possible
common sexual transmission of multiple HR HPV types, and
suggesting that multiple infection is associated with all stages
of cervical lesions [13,15,17]. Our data showed an increased
two-fold risk for developing CIN2+ lesions in women with
multiple HPV infection, suggesting that multiple HPV types
might lead to persistency and might identify a subset of
women at higher risk of high-grade CIN. These results are in
agreement with those of other cross-sectional and prospec-
tive studies [14,16,18,19,21,22].
There were some limitations to this study. The women
included cannot be considered to be a representative sample
of Portuguese women. Another potential limitation may orig-
inate from the fact that cross-sectional detection of type-
speciﬁc HPV infections may underestimate the cumulative
lifetime diversity of exposure to HPV.
Knowledge of the prevalence and natural history of type-
speciﬁc HPV, either as single or multiple infections, in the
development of cervical neoplasia will be important for an
appropriate intervention in cervical cancer prevention pro-
grammes, to identify women at risk of pre-cancerous cervical
lesions, and to understand the potential impact of HPV vac-
cines in the population.
In conclusion, the ﬁndings presented in this study describe
the HPV type distribution among women diagnosed with or
without cervical neoplasia in Portugal. HPV 16, 31, 53, 66, 58
and 51 were the most common genotypes. HPV vaccine
types 6, 11, 16 and 18 together were detected in 41.8% of
positive women. Multiple infections were more frequent in
women under 30 years of age, and showed a signiﬁcant
increase according to severity of cervical neoplasia, particu-
larly for HR–HR HPV infections.
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